English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity

MPS-Authors
/persons/resource/persons282255

Bozlar,  Muege
IMPRS, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Kennel, K. B., Bozlar, M., De Valk, A. F., & Greten, F. R. (2023). Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity. CLINICAL CANCER RESEARCH, 29(6), 1009-1016. doi:10.1158/1078-0432.CCR-22-1031.


Cite as: https://hdl.handle.net/21.11116/0000-000D-121A-2
Abstract
Tumor-associated inflammation (TAI) is a feature of essen-tially all cancers and can confer both tumor-promoting and-suppressive functions. Cancer-associated fibroblasts (CAF) comprise one very heterogeneous cellular component of the tumor microenvironment characterized by a high degree of plasticity. Recent single-cell sequencing analyses revealed dis-tinct CAF populations in various human cancers and helped to define key CAF subtypes, such as myofibroblastic, inflammatory, and antigen-presenting CAFs, with the first two being present in virtually all tumors. Importantly, these three CAF populations are involved in and modulate the positive and negative con-sequences of TAI. The remarkable plasticity of CAFs allows them to shift phenotypically and functionally in response to environ-mental changes. In this review, we describe how CAFs nurture tumor-promoting inflammation and suppress adaptive immu-nity. We also summarize the recently emerging evidence per-taining to tumor-suppressive CAF functions in the context of TAI. Finally, we summarize therapeutic concepts that aim at modulating CAF functions or depleting immunosuppressive CAFs to synergize with immunotherapy.